Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$10.60−0.04 (-0.38%)
Close on Nov 16, 2026Market cap $891.68MP/E –Yield –
Corvus Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Corvus Pharmaceuticals
Corvus Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?